@article{639b4a866f704422955cc1e1c2087de3,
title = "Multifocal, Asymmetric Bilateral Primary Aldosteronism Cannot be Excluded by Strong Adrenal Vein Sampling Lateralization: An International Retrospective Cohort Study",
abstract = "BACKGROUND: Primary aldosteronism (PA) has been broadly dichotomized into unilateral and bilateral forms. Adrenal vein sampling (AVS) lateralization indices (LI) ≥2 to 4 are the standard-of-care to recommend unilateral adrenalectomy for presumed unilateral PA. We aimed to assess the rates and characteristics of residual PA after AVS-guided adrenalectomy. METHODS: We conducted an international, retrospective, cohort study of patients with PA from 7 referral centers who underwent unilateral adrenalectomy based on LI≥4 on baseline and/or cosyntropin-stimulated AVS. Aldosterone synthase (CYP11B2) immunohistochemistry and next generation sequencing were performed on available formalin-fixed paraffin-embedded adrenal tissue. RESULTS: The cohort included 283 patients who underwent AVS-guided adrenalectomy, followed for a median of 326 days postoperatively. Lack of PA cure was observed in 16\% of consecutive patients, and in 22 patients with lateralized PA on both baseline and cosyntropin-stimulated AVS. Among patients with residual PA postoperatively, 73\% had multiple CYP11B2 positive areas within the resected adrenal tissue (versus 23\% in those cured), wherein CACNA1D mutations were most prevalent (63\% versus 33\% in those cured). In adjusted regression models, independent predictors of postoperative residual PA included Black versus White race (odds ratio, 5.10 [95\% CI, 1.45-17.86]), AVS lateralization only at baseline (odds ratio, 8.93 [95\% CI 3.00-26.32] versus both at baseline and after cosyntropin stimulation), and CT-AVS disagreement (odds ratio, 2.75 [95\% CI, 1.20-6.31]). CONCLUSIONS: Multifocal, asymmetrical bilateral PA is relatively common, and it cannot be excluded by robust AVS lateralization. Long-term postoperative monitoring should be routinely pursued, to identify residual PA and afford timely initiation of targeted medical therapy.",
keywords = "adrenal glands, aldosterone, blood pressure, hypertension, renin",
author = "Turcu, \{Adina F.\} and Yuta Tezuka and Lim, \{Jung Soo\} and Zara Salman and Kartik Sehgal and Haiping Liu and St{\'e}phanie Larose and Parksook, \{Wasita Warachit\} and Williams, \{Tracy Ann\} and Cohen, \{Debbie L.\} and Heather Wachtel and Jinghong Zhang and Pranav Dorwal and Fumitoshi Satoh and Jun Yang and Andr{\'e} Lacroix and Martin Reincke and Giordano, \{Tom J.\} and Udager, \{Aaron M.\} and Anand Vaidya and Rainey, \{William E.\}",
note = "Funding Information: J. Yang has received project support from DiaSorin Pty Ltd and is supported by a Fellowship from the National Health and Medical Research Council of Australia. A. Vaidya reports consulting fees unrelated to the contents of this work from Corcept Therapeutics, Mineralys, HRA Pharma. A.F. Turcu served as local investigator in a clinical trial conducted by CinCor/AstraZeneca. All other authors declare no conflict of interest. Funding Information: A.F. Turcu was supported by grant 2019087 from the Doris Duke Charitable Foundation, and R01HL155834 from the National Heart, Lung, and Blood Institute. W.E. Rainey was supported by grant DK106618 from the National Institute of Diabetes and Digestive and Kidney Disease. A. Vaidya is supported by the National Institutes of Health (Awards R01 DK115392, R01 HL153004, R01 DK16618, and R01 HL155834). T.A. Williams is supported by grants from the Deutsche Forschungsgemeinschaft (DFG; WI 5359/2-1 and 314061271-TRR 205). M. Reincke is supported by grants from the Else Kr{\"o}ner-Fresenius Stiftung in support of the German Conn{\textquoteright}s Registry-Else-Kr{\"o}ner Hyperaldosteronism Registry (2013\_A182, 2015\_A171 and 2019\_A104), the European Research Council under the European Union{\textquoteright}s Horizon 2020 research and innovation program (grant agreement No 694913 to M. Reincke), and the DFG (within the CRC/Transregio205/2 The Adrenal: Central Relay in Health and Disease). H. Wachtel is supported by the National Cancer Institute of the National Institutes of Health, grant K08 CA270385. Publisher Copyright: {\textcopyright} 2024 Lippincott Williams and Wilkins. All rights reserved.",
year = "2024",
month = mar,
doi = "10.1161/HYPERTENSIONAHA.123.21910",
language = "English",
volume = "81",
pages = "604--613",
journal = "Hypertension",
issn = "0194-911X",
publisher = "American Heart Association",
number = "3",
}